title: Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
abstract: This study analyzed the effects of dutasteride on lower urinary tract symptoms based on the association between changes in the total testosterone (TT)/dihydrotestosterone (DHT) levels and total prostate volume (TPV) reduction. Sixty participants diagnosed with benign prostatic hyperplasia were given 0.5 mg of dutasteride daily for 52 weeks. Measures of TT and DHT levels, TPV and uroflowmetry were obtained before and after dutasteride treatment. Forty-three patients demonstrated a TPV reduction of ≥5% (Group 1), whereas the remaining 17 patients demonstrated a TPV reduction of <5% (Group 2). DHT suppression and DHT/TT ratio at baseline were significantly higher in Group 1 than Group 2. International Prostate Symptom Scores (IPSS) and uroflowmetry were significantly improved in both groups. In Group 2, nine patients demonstrated some improvement in IPSS (Group 2A), whereas eight did not (Group 2B). The rate of TT increase and improvement in voiding symptoms were significantly higher in Group 2A than Group 2B. Dutasteride-induced TPV reduction is dependent on individual 5-α reductase inhibitor activity. Some patients demonstrating smaller dutasteride-induced TPV reduction may experience an improvement in voiding symptoms owing to an increased level of testosterone.
authors.affiliation: a Department of Urology , Ishikawa Prefectural Central Hospital , Kanazawa , Japan .|b Department of Urology , Kanazawa University Graduate School of Medical Science , Kanazawa , Japan .
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Shigehara
authors.affiliation: a Department of Urology , Ishikawa Prefectural Central Hospital , Kanazawa , Japan .
authors.forename: Tohru
authors.initials: T
authors.lastname: Miyagi
authors.affiliation: a Department of Urology , Ishikawa Prefectural Central Hospital , Kanazawa , Japan .
authors.forename: Takao
authors.initials: T
authors.lastname: Nakashima
authors.affiliation: b Department of Urology , Kanazawa University Graduate School of Medical Science , Kanazawa , Japan .
authors.forename: Koji
authors.initials: K
authors.lastname: Izumi
authors.affiliation: b Department of Urology , Kanazawa University Graduate School of Medical Science , Kanazawa , Japan .
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Kitagawa
authors.affiliation: b Department of Urology , Kanazawa University Graduate School of Medical Science , Kanazawa , Japan .
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.affiliation: c Department of Urology , Showa Inan Medical Hospital , Komagane , Japan , and.
authors.forename: Eitetsu
authors.initials: E
authors.lastname: Koh
authors.affiliation: d Department of Urology , Nomi City Hospital , Nomi , Japan.
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Shimamura
authors.affiliation: b Department of Urology , Kanazawa University Graduate School of Medical Science , Kanazawa , Japan .
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000097:blood*; D000068538:Dutasteride / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011446:Prospective Studies; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*
chemical_list: D058891:5-alpha Reductase Inhibitors; D013196:Dihydrotestosterone; D013739:Testosterone; D000068538:Dutasteride
keywords: Dutasteride; benign prostatic hyperplasia; dihydrotestosterone; lower urinary tract symptoms; testosterone